3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
25
Phase 1
4
Phase 3
3
Phase NA
1
Phase 2/3
1
Phase 1/2
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Carcinoma, Renal Cell
10
Breast Neoplasms
5
Sarcoma
2
Prostatic Neoplasms
2
Melanoma
2
Gastrointestinal Stromal Tumors
2
Urinary Bladder Neoplasms
1
Solitary Fibrous Tumors
1
Solid Tumors Refractory to Standard Therapy
1
Small Cell Lung Carcinoma
1
Sarcoma, Synovial
1
Sarcoma, Ewing
1
Sarcoma, Clear Cell
1
Sarcoma, Alveolar Soft Part
1
Osteosarcoma
1
Neoplasms
1
Neoplasm Metastasis
1
Leukemia, Myeloid, Acute
1
Leiomyosarcoma
1
Kidney Neoplasms
1
Histiocytoma, Malignant Fibrous
1
Hemangiosarcoma
1
Hemangioendothelioma, Epithelioid
1
Hemangioendothelioma
1
Fatigue
1
Colorectal Neoplasms
1
Chondrosarcoma, Extraskeletal Myxoid
1
Chondrosarcoma
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Hepatocellular
1
Interventions
pembrolizumab
43
Nivolumab
24
Gemcitabine
23
Cyclophosphamide
21
Paclitaxel
17
Capecitabine
16
fludarabine
14
Ipilimumab
14
aldesleukin
11
Docetaxel
11
130-nm albumin-bound paclitaxel
11
Trastuzumab
10
Cetuximab
10
Bevacizumab
10
Albumin-Bound Paclitaxel
9
fludarabine phosphate
8
Specimen Handling
8
Interleukin-2
8
Fluorouracil
8
Cisplatin
8
Biopsy
8
Radiosurgery
7
Oxaliplatin
7
Irinotecan
7
durvalumab
6
avelumab
6
Temozolomide
6
Pemetrexed
6
Leucovorin
6
Carboplatin
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Neoplasm Metastasis
×
Sunitinib
×
Clear all
NCT00905021
2020-07-24
EXTENT
Baylor Breast Care Center
Phase 1/2
Terminated
4 enrolled
6 charts